(Total Views: 392)
Posted On: 09/29/2020 4:12:03 PM
Post# of 145247
If CD12 performs similar to CD10 NEWS2 score over placebo, the p value would be less than .02 at the interim assuming a 20% mortality rate of placebo. To achieve statistical power of 80% at the interim mortality rate has to be a lot higher unfortunately for the trial to be stopped. DSMC would most likely recommend trial to continue but CYDY can afford to share results and pay a penalty imho.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)